Literature DB >> 34541029

The Hippo pathway: an emerging role in urologic cancers.

Bekir Cinar1, Esma Alp1, Marwah Al-Mathkour1, Ava Boston1, Abdulrahman Dwead1, Kezhan Khazaw1, Alexis Gregory1.   

Abstract

The Hippo pathway controls several biological processes, including cell growth, differentiation, motility, stemness, cell contact, immune cell maturation, organ size, and tumorigenesis. The Hippo pathway core kinases MST1/2 and LATS1/2 in mammals phosphorylate and inactivate YAP1 signaling. Increasing evidence indicates that loss of MST1/2 and LATS1/2 function is linked to the biology of many cancer types with poorer outcomes, likely due to the activation of oncogenic YAP1/TEAD signaling. Therefore, there is a renewed interest in blocking the YAP1/TEAD functions to prevent cancer growth. This review introduces the Hippo pathway components and examines their role and therapeutic potentials in prostate, kidney, and bladder cancer. AJCEU
Copyright © 2021.

Entities:  

Keywords:  Hippo pathway; LATS1; LATS2; MST1/STK3; MST1/STK4; YAP1; cancer biology; signal transduction; urologic cancer

Year:  2021        PMID: 34541029      PMCID: PMC8446764     

Source DB:  PubMed          Journal:  Am J Clin Exp Urol        ISSN: 2330-1910


  167 in total

Review 1.  Emerging Variants of Castration-Resistant Prostate Cancer.

Authors:  Panagiotis J Vlachostergios; Loredana Puca; Himisha Beltran
Journal:  Curr Oncol Rep       Date:  2017-05       Impact factor: 5.075

2.  A gp130-Src-YAP module links inflammation to epithelial regeneration.

Authors:  Koji Taniguchi; Li-Wha Wu; Sergei I Grivennikov; Petrus R de Jong; Ian Lian; Fa-Xing Yu; Kepeng Wang; Samuel B Ho; Brigid S Boland; John T Chang; William J Sandborn; Gary Hardiman; Eyal Raz; Yoshihiko Maehara; Akihiko Yoshimura; Jessica Zucman-Rossi; Kun-Liang Guan; Michael Karin
Journal:  Nature       Date:  2015-02-25       Impact factor: 49.962

3.  Integrative clinical genomics of advanced prostate cancer.

Authors:  Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

4.  Cell growth density modulates cancer cell vascular invasion via Hippo pathway activity and CXCR2 signaling.

Authors:  G M Sharif; M O Schmidt; C Yi; Z Hu; B R Haddad; E Glasgow; A T Riegel; A Wellstein
Journal:  Oncogene       Date:  2015-03-16       Impact factor: 9.867

5.  The Immunoexpression of YAP1 and LATS1 Proteins in Clear Cell Renal Cell Carcinoma: Impact on Patients' Survival.

Authors:  J Godlewski; J Kiezun; B E Krazinski; Z Kozielec; P M Wierzbicki; Z Kmiec
Journal:  Biomed Res Int       Date:  2018-04-03       Impact factor: 3.411

6.  FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis.

Authors:  S Pauliina Turunen; Pernilla von Nandelstadh; Tiina Öhman; Erika Gucciardo; Brinton Seashore-Ludlow; Beatriz Martins; Ville Rantanen; Huini Li; Katrin Höpfner; Päivi Östling; Markku Varjosalo; Kaisa Lehti
Journal:  Cell Death Differ       Date:  2019-03-22       Impact factor: 15.828

7.  YAP Triggers Bladder Cancer Proliferation by Affecting the MAPK Pathway.

Authors:  Dandan Qiu; Yan Zhu; Zhicheng Cong
Journal:  Cancer Manag Res       Date:  2020-11-27       Impact factor: 3.989

8.  The role of androgen receptor mutations in prostate cancer progression.

Authors:  G N Brooke; C L Bevan
Journal:  Curr Genomics       Date:  2009-03       Impact factor: 2.236

9.  Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death.

Authors:  Emarndeena H Cheteh; Martin Augsten; Helene Rundqvist; Julie Bianchi; Victoria Sarne; Lars Egevad; Vladimir Jn Bykov; Arne Östman; Klas G Wiman
Journal:  Cell Death Dis       Date:  2017-06-01       Impact factor: 8.469

10.  Clinical effects of curcumin in enhancing cancer therapy: A systematic review.

Authors:  Kamran Mansouri; Shna Rasoulpoor; Alireza Daneshkhah; Soroush Abolfathi; Nader Salari; Masoud Mohammadi; Shabnam Rasoulpoor; Shervin Shabani
Journal:  BMC Cancer       Date:  2020-08-24       Impact factor: 4.430

View more
  2 in total

1.  The Hippo effector YAP1/TEAD1 regulates EPHA3 expression to control cell contact and motility.

Authors:  Marwah M Al-Mathkour; Abdulrahman M Dwead; Esma Alp; Ava M Boston; Bekir Cinar
Journal:  Sci Rep       Date:  2022-03-09       Impact factor: 4.379

Review 2.  The Hippo pathway and its correlation with acute kidney injury.

Authors:  Chi Zhang; Chuan-Lei Li; Ke-Xin Xu; Zhi-Huang Zheng; Guo-Zhe Cheng; Hui-Juan Wu; Jun Liu
Journal:  Zool Res       Date:  2022-09-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.